ArticleInternational journal of clinical and experimental pathology2010
Selective central nervous system tropism of primary central nervous system lymphoma.
Article in International journal of clinical and experimental pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Genetic orchestration of the primary central nervous system lymphoma microenvironment.Biomarker research · 2026Review
- Role and application of chemokine CXCL13 in central nervous system lymphoma.Annals of hematology · 2024Review
- Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes.PLoS pathogens · 2021Article
- Osteopontin expression and its relationship with prognostic factors in diffuse large B-cell lymphoma.Hematology reports · 2019Article
- Biomarkers Reflecting The Destruction Of The Blood-Brain Barrier Are Valuable In Predicting The Risk Of Lymphomas With Central Nervous System Involvement.OncoTargets and therapy · 2019Article
- Article
- Osteopontin at the Crossroads of Inflammation and Tumor Progression.Mediators of inflammation · 2017Review
- Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.Journal of neuro-oncology · 2016Article
- Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma.Oncotarget · 2016Article
- Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies.Journal of neuro-oncology · 2015Review
- Article
- Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma.International journal of clinical and experimental pathology · 2012Article
- Murine models of B-cell lymphomas: promising tools for designing cancer therapies.Advances in hematology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary Central nervous system lymphoma (PCNSL) is most frequently a diffuse large B cell lymphoma (DLBCL), which is confined to the Central nervous system (CNS). We performed an experiment in which lymphoma cells from a PCNSL patient were implanted subcutaneously in an athymic mouse. The lymphoma cells were shown to home to the CNS with histologic evaluations of the brain showing multiple large B cells in blood vessels consistent with intravascular large B cell lymphoma (IVL). We did not find any evidence of lymphoma at the site of implantation or other locations. The findings are consistent with highly selective tropism of PCNSLforthe CNS and its vasculature.
Indexed as
Identifiers
21151389PMC2993226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.